Abstract
Chemotherapy continues to be, along with radiotherapy and surgery, an extremely efficient approach in cancer therapy. Much progress has been made in the last 25 years that allows us to consider several types of cancer as “curable” by chemotherapy. These cures can be obtained for cancers as different as: Hodgkin’s disease, large cell lymphoma, acute lymphocytic leukemia, testicular cancer and early stage breast cancer1. Furthermore with the development of combination chemotherapy, other malignancies such as ovarian, small cell lung cancer, and advanced breast cancer, though not yet curable, demonstrate interesting clinical responses in many patients.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
B. A. Chabner, R. L. Fine, C. L. Allegre, Cancer chemotherapy: progress and expectations, Cancer 54: 2599–2608(1984).
W. R. Waud and D.R Griswald, Therapeutic Resistance in Leukemia, in “Drug Resistance in Oncology”, B. A. Teicher, ed., Dekker, N—Y, 227–250 (1993).
B. A. Teicher, In vivo resistance to antitumor alkylating agents, in “Drug Resistance in Oncology”, B. A. Teicher, ed., N—Y, 263–290 (1993).
J. D. Hayes and CR. Wolf, Molecular mechanisms of drug resistance, Biochem. J. 272:281–230 (1985).
J. H. Goldie, A. J. Coldman, Genetic instability in the development of drug resistance, Semin. Oncol. 12: 222–230(1985).
Y. Canitrot, D. Lautier, S. Lahmy, J. Vigo, P. Viallet and J. M. Salmon, Nile red labeling of single living cells for contour delineation to quantity and evoluate the distribution of rhodamine 123 with fluorescence image cytometry, Histochem. Cytochem. 41: 1785–1793 (1993).
Y. Canitrot, Chimiothérapie et résistance: la rhodamine 123 comme marqueur de la résistance pléiot—ropique. Apport de l’analyse d’images de fluorescence numérisées à la discrimination de cellules sensibles et résistantes, Thèse, Université de Perpignan: 201 p.(1994).
D. Lautier, Y Canitrot and J. M. Salmon, Effects of vinblastine, colchicine and verapamil on rhodamine 123 accumulation in human p—glycoprotein—positive leukemia cells, Anticancer Research 14: 2589–2596 (1994).
T.J. Lampidis, C. Castello, A. Del Giglio, B. Pressman, P. Viallet, H. W. Ptrvorrow, G. K. Valet, Tapiedo H. and N. Savaraj, Relevance of the chemical charge of Rhodamine dyes multiple drug resistance. Biochem. Pharmacol. 38: 4267–4271 (1989).
W. T. Beck, M. C. Cirtain, A. T. Look and R. A. Ashum, Reversal of vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil, Cancer Research 46: 778–784 (1986).
M. K. Danks, J. C. Yalowich and W. T Beck, Atypical multiple drug resistance in a human leukemia cell line selected for resistance to tenoposide (VM -26) 1, Cancer Research 47: 1297–1301 (1987).
W.T. Beck, T.J Mueller and L.R. Tanzer, Altered surface membrane glycoproteine in Vinca alkaloïd-resistant human leukemic lymphoblasts, Cancer Research 39: 2070–2076 (1979).
J. M. Salmon, Y. Canitrot, D. Lauttier, S. Lahmy, J. Vigo and P. Viallet, Multiwavelenght videomi-crofluorimetry and multiparametric analysis: application to the detection of multidrug resistance in single living cells, J. Cell Pharmacol. 3: 86–94 (1992).
J. Vigo, J. M. Salmon, S. Lahmy and P. viallet. Fluorescence image cytometry: from qualitative measurement, Anal. Cell Pathol. 3: 145–165 (1991).
Y Canitrot, D. Lautier, J. Vigo, P. Viallet and J. M Salmon, Nile red labeling of single living cells for contour delineation to quantify and evaluate the distribution of rhodamine 123 with fluorescence image cytometry, J. Histochem. Cytochem. 41: 1785–1793 (1993).
S. Lahmy, J. M. Salmon, J. Vigo and P. Viallet, pHi and DNA content modifications after ADR treatment in 3T3 fibroblasts. A microfluorometric approach. Anticancer Research 9: 929–936 (1989).
M. Israel, R. Seshadri, Y Yoseki, M. Potmesil, S. Kirschenbaum, R. Silber, A. Bodley, L.F. Liu and T.P Brent, New anthracyclines analogues against DNA topoisomerase II, in Anticancer drugs, Eds. H. Tapiero, J. Robert, T.J. Lampidis, Colloque INSERM/John Libbey Eurotext, 191: 39–47 (1989).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Salmon, JM., Rocchi, E., Vigo, J., Viallet, P. (1996). Multiwavelength MicroFluorometry to Investigate Cytotoxic Processes on Sensitive and Resistant Human Lymphoblastoid CCRF-Cem Lines. In: Kohen, E., Hirschberg, J.G. (eds) Analytical Use of Fluorescent Probes in Oncology. NATO ASI Series, vol 286. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5845-3_23
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5845-3_23
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7679-8
Online ISBN: 978-1-4615-5845-3
eBook Packages: Springer Book Archive